Although still trading near its 52-week low, Amgen Inc. got a boost at the end of January thanks to better than expected earnings and new data showing that osteoporosis drug denosumab outperformed Fosamax (alendronate, Merck & Co. Inc.) in a Phase III trial. (BioWorld Financial Watch)